Bristol-Myers sues Merck in US over PD-1 patent
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb received US patent protection for methods of treating cancer with an antibody that inhibits programmed cell death-1 (PD-1) in May, but waited until Merck & Co's Keytruda (pembrolizumab) won US FDA approval for melanoma to sue for patent infringement.